Advertisement
UK markets closed

  • FTSE 100

    8,139.83
    +60.97 (+0.75%)
     

  • FTSE 250

    19,824.16
    +222.18 (+1.13%)
     

  • AIM

    755.28
    +2.16 (+0.29%)
     

  • GBP/EUR

    1.1675
    +0.0018 (+0.16%)
     

  • GBP/USD

    1.2487
    -0.0024 (-0.19%)
     

  • Bitcoin GBP

    50,981.60
    -475.89 (-0.92%)
     

  • CMC Crypto 200

    1,326.16
    -70.37 (-5.04%)
     

  • S&P 500

    5,107.14
    +58.72 (+1.16%)
     

  • DOW

    38,283.64
    +197.84 (+0.52%)
     

  • CRUDE OIL

    84.04
    +0.47 (+0.56%)
     

  • GOLD FUTURES

    2,346.60
    +4.10 (+0.18%)
     

  • NIKKEI 225

    37,934.76
    +306.28 (+0.81%)
     

  • HANG SENG

    17,651.15
    +366.61 (+2.12%)
     

  • DAX

    18,161.01
    +243.73 (+1.36%)
     

  • CAC 40

    8,088.24
    +71.59 (+0.89%)
     
PROPERTY:

9 luxury homes to consider if money is no object

Ever thought about what a multimillion pound budget would buy you?

Here's Why Agenus Rose as Much as 23.3% Today

Maxx Chatsko, The Motley Fool
·3-min read
Here's Why Agenus Rose as Much as 23.3% Today

Shares of Agenus (NASDAQ: AGEN) jumped over 23% today after the company announced a presentation at the American Society of Clinical Oncology (ASCO) meeting discussing the progress of AGEN1181 in solid-tumor cancers. The drug candidate delivered clinical benefit in 70% of patients with advanced tumors in the small-scale study, both as a monotherapy and in combination with another drug candidate from the company. If the results can hold up in larger clinical trials, AGEN1181 might have broad potential to improve outcomes for patients with a wide array of solid tumor cancers.

Continue reading